APA (7th ed.) Citation

SR, D., DPS, D., MW, S., Y, M., JD, C., G, E., . . . NA, M. (2026). AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial. The Journal of allergy and clinical immunology. https://doi.org/10.1016/j.jaci.2026.03.026

Chicago Style (17th ed.) Citation

SR, Doffman, et al. "AZD8630/AMG 104, an Inhaled Anti-thymic Stromal Lymphopoietin Antibody Fragment, for Moderate-to-severe Asthma: Phase 1 Randomized Controlled Trial." The Journal of Allergy and Clinical Immunology 2026. https://doi.org/10.1016/j.jaci.2026.03.026.

MLA (9th ed.) Citation

SR, Doffman, et al. "AZD8630/AMG 104, an Inhaled Anti-thymic Stromal Lymphopoietin Antibody Fragment, for Moderate-to-severe Asthma: Phase 1 Randomized Controlled Trial." The Journal of Allergy and Clinical Immunology, 2026, https://doi.org/10.1016/j.jaci.2026.03.026.